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ABSTRACT
Clinical trials of tolvaptan showed it to be a promising candidate for the treatment of Autosomal Dominant Polycystic
Kidney Disease (ADPKD) but also revealed potential for idiosyncratic drug-induced liver injury (DILI) in this patient
population. To identify risk factors and mechanisms underlying tolvaptan DILI, 8 mice in each of 45 strains of the
genetically diverse Collaborative Cross (CC) mouse population were treated with a single oral dose of either tolvaptan or
vehicle. Significant elevations in plasma alanine aminotransferase (ALT) were observed in tolvaptan-treated animals in 3 of
the 45 strains. Genetic mapping coupled with transcriptomic analysis in the liver was used to identify several candidate
susceptibility genes including epoxide hydrolase 2, interferon regulatory factor 3, and mitochondrial fission factor. Gene
pathway analysis revealed that oxidative stress and immune response pathways were activated in response to tolvaptan
treatment across all strains, but genes involved in regulation of bile acid homeostasis were most associated with tolvaptan-
induced elevations in ALT. Secretory leukocyte peptidase inhibitor (Slpi) mRNA was also induced in the susceptible strains
and was associated with increased plasma levels of Slpi protein, suggesting a potential serum marker for DILI susceptibility.
In summary, tolvaptan induced signs of oxidative stress, mitochondrial dysfunction, and innate immune response in all
strains, but variation in bile acid homeostasis was most associated with susceptibility to the liver response. This CC study
has indicated potential mechanisms underlying tolvaptan DILI and biomarkers of susceptibility that may be useful in
managing the risk of DILI in ADPKD patients.
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Tolvaptan is a vasopressin V2-receptor antagonist marketed for
the treatment of hyponatremia. Tolvaptan has also been
approved for the treatment of autosomal dominant polycystic
kidney disease (ADPKD) in some regions (Torres et al., 2012).
However, the U.S. Food and Drug Administration approval for
this indication has not yet been received, in part due to reported
cases of drug-induced liver injury (DILI) associated with tolvap-
tan use in ADPKD patients.
Hepatotoxicity is relatively rare in tolvaptan-treated ADPKD
patients and has not been observed in non-ADPKD patients
treated with tolvaptan (Watkins et al., 2015). Furthermore, non-
clinical testing of tolvaptan in traditional animal models (mice,
rats, and dogs) did not indicate a risk for liver injury (Oi et al.,
2011). Studying the mechanisms and identifying risk factors
associated with tolvaptan hepatotoxicity has therefore been
challenging.
Previous studies have demonstrated the ability of mouse
genetic reference populations (GRPs) to model the drug-induced
injury observed in humans better than traditional nonclinical
animal models (Harrill et al., 2012). GRPs have also been utilized
for pharmacogenomic analysis to identify risk factors associ-
ated with drug-induced adverse events in liver and kidney
(Harrill et al., 2009, 2012; Mosedale et al., 2014). Importantly, find-
ings in GRP mice translate to DILI risk factors in humans (Court
et al., 2013; Harrill et al., 2009).
The Collaborative Cross (CC) is a recently developed and highly
sophisticated GRP composed of multiparental recombinant inbred
lines. This population was strategically designed to overcome
limitations of classical inbred GRPs such as population structure
and blind spots of genomic variation. The CC strains have high
genetic diversity, balanced allele frequencies, and dense, evenly
distributed recombination sites (Collaborative Cross Consortium,
2012). Using diverse and genetically defined strains can increase
the statistical power to detect the effects of a test chemical
(Festing, 2010). Studies with CC strains have demonstrated that
the diversity of responses observed in this population is more ex-
tensive than standard inbred strain panels (Kelada et al., 2014;
Rutledge et al., 2014). Therefore, it was hypothesized that evaluat-
ing tolvaptan-induced liver responses within the CC may help to
identify strains sensitive to liver injury. These strains could then
be used to provide a mechanistic understanding and identify
potential risk factors associated with susceptibility to tolvaptan
hepatotoxicity in the ADPKD patient population.
Although traditional histological and biochemical endpoints
can be used for the identification of a toxic response, recent evi-
dence suggests liver gene expression analysis after a single,
maximally tolerated dose may be a more sensitive and transla-
tional method to predict an adverse drug response in humans
(Laifenfeld et al., 2014; Leone et al., 2014). Furthermore, evalu-
ation of molecular signaling pathways can provide insight into
mechanisms of drug toxicity as well as phenotypes for quantita-
tive trait loci (QTL) mapping, even in the absence of overt injury.
Based on these findings, traditional biochemical and histolo-
gical endpoints as well as gene expression profiling were per-
formed in this study.
Finally, it must be noted that clinical tolvaptan DILI cases
were typically delayed in onset, presenting between 3 and 18
months of treatment, and exhibited a relatively prompt recur-
rence upon re-challenge, supporting the involvement of the
adaptive immune system in the final critical events underlying
the liver injury (Watkins et al., 2015). This CC study was not
designed to allow for the evaluation of an adaptive immune re-
sponse. However, it has been hypothesized that even if an adap-
tive immune attack is the final insult responsible for eliciting
overt liver injury, events that are necessary but not sufficient for
the liver injury begin at the hepatocyte level and result in the re-
lease of “danger signals” that are important for activating the im-
mune response (Kaplowitz, 2005; Li and Uetrecht, 2010; Mosedale
and Watkins, 2016). These early events may require both genetic
and nongenetic susceptibility factors that contribute to the idio-
syncratic nature of the drug reaction. Therefore, a liver response
in sensitive CC strains could have mechanistic similarities to the
early hepatocellular events occurring in the ADPKD patients.
Thus, to gain insight into potential mechanisms of tolvaptan
hepatotoxicity and to generate testable hypotheses regarding risk
factors for liver injury in humans, phenotypic findings in combin-
ation with genetics and transcriptomics were used to identify
variation in specific genes and pathways associated with suscep-
tibility to tolvaptan DILI in the CC mice.
MATERIALS ANDMETHODS
Animals. The CC is a panel of recombinant inbred lines derived
from 8 inbred founder mouse strains (short names in parenthe-
ses): 129S1/SvlmJ (129S1), A/J (AJ), C57BL/6J (B6), NOD/ShiLtJ
(NOD), NZO/HILtJ (NZO), CAST/EiJ (CAST), PWK/PhJ (PWK), and
WSB/EiJ (WSB). The initiation of the CC breeding funnels,
description of the CC strains, and animal housing are described
elsewhere (Collaborative Cross Consortium, 2012). Eight male
mice from each of 45 CC lines (listed on the x-axis of Figure 1)
were purchased from the University of North Carolina, Chapel
Hill (UNC). All lines came from independent breeding funnels
except for 2, CC051/TauUnc and CC059/TauUnc, which descended
from the same breeding funnel and were separated at a later gen-
eration. Animals were housed in polycarbonate cages, kept on a
12-h light-dark cycle and provided Pelleted PicoLab Rodent Diet 20
(Lab Diet) ad libitum, except during an approximate 18-h period of
fasting prior to necropsy. Animals were acclimated for approxi-
mately 7 days prior to dosing. At the initiation of dosing, mice
were approximately 8–10 weeks of age. Care of mice followed
institutional guidelines under a protocol approved by Mispro
Biotech Services Institutional Animal Care and Use Committee.
Clinical assessments were performed using previously described
methods (Burkholder et al., 2012).
Experimental Design. An acute, high-dose exposure study design
was selected to enable the use of liver gene expression profiling
as an endpoint for the hepatotoxic response (Laifenfeld et al.,
2014; Leone et al., 2014). This approach helps to maximize
responses at the gene expression level while limiting the oppor-
tunity for adaptation. Within each strain, animals were treated
with a single oral (gavage) dose of either vehicle (hydroxypropyl
methylcellulose; Sigma) or 100 mg/kg tolvaptan (provided by
Otsuka Pharmaceutical Co. Ltd) in a dosing volume of 10 ml/kg.
The dose selected was based on previous studies of tolvaptan in
CD-1 and B6C3F1 mice (Oi et al., 2011), but reduced 3-fold below
the maximally tolerated dose (300 mg/kg in B6C3F1 per nonclini-
cal study reports) based on the predicted increased sensitivity
of some CC strains. Animals were randomly assigned to treat-
ment groups (N¼4 per group, per strain) using a randomization
method based on bodyweight. Vehicle- and tolvaptan-treated
animals within each strain were treated in pairs, and pairs
within each strain were randomized over the course of the study
to minimize batch (delivery group) effects.
Whole blood (approximately 100 ml) was collected from all
vehicle- and tolvaptan-treated mice at 2 h postdosing (approxi-
mate Tmax in mice). Blood was collected from the submandibular
(facial) vein or, if necessary, the tail vein or lateral saphenous
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FIG. 1. Tolvaptan induces elevations in plasma ALT in sensitive CC strains. A, Average plasma ALT for vehicle- (white circles) and tolvaptan-treated (black squares) ani-
mals. *p<.05 and ***p<.001 indicate the difference between vehicle- and tolvaptan-treated animals within each strain (Bonferroni posttest). B, Average fold change in
ALT between pairs of vehicle- and tolvaptan-treated animals within each strain. C, Average plasma tolvaptan concentrations at 2 h postdose and D, 24 h postdose.
Data in all panels are represented as mean þ SE of N¼4 animals or pairs per strain and/or group, except as noted in the text. Strains are ordered from left to right by
increasing average fold change in ALT between pairs of vehicle- and tolvaptan-treated animals within each strain.
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vein. Blood was transferred to a tube containing sodium heparin
and processed into plasma for analysis of tolvaptan and
DM-4103 (a primary human tolvaptan metabolite contributing
to >10% systemic exposure) concentrations.
Animals were food fasted at 6 h postdosing (to reduce hep-
atic glycogen levels and improve histopathological assessment)
and sacrificed at 24 h postdosing by CO2 inhalation followed by
exsanguination. Blood was collected by cardiac puncture.
Approximately 100 ml of blood from tolvaptan-treated animals
was transferred into a tube containing sodium heparin and
processed into plasma for analysis of tolvaptan and DM-4103
concentrations. The remaining blood was transferred into a
microcentrifuge tube containing EDTA and processed into
plasma for clinical chemistry. The liver of each animal was
excised and weighed. A section of the left and median liver
lobes was fixed in 10% neutral buffered formalin and processed
for histological analysis. A section of liver tissue encompassing
all regions of the median lobe was diced, placed in RNAlater
(Ambion), and processed for gene expression analysis.
Plasma Drug Concentration. Heparin-treated plasma was shipped
to ICON Development Solutions, Whitesboro, NY. Concentrations
of parent drug and DM-4103 were determined using reversed-
phase liquid chromatography with Turbo IonSpray tandem mass
spectrometric detection (LC-MS/MS). Tolvaptan, DM-4103, and an
internal standard were extracted from heparinized plasma using
solid phase extraction. Calibration standards prepared in plasma
and extracted along with samples were used to quantitate the
concentrations by weighted (1/x2) linear regression of peak area
ratios of analyte-to-internal standard.
Clinical Chemistry. EDTA-treated plasma was subjected to an
additional centrifugation step at 16 000  g for 10 min before
freezing and transfer to ANTECH GLP, Research Triangle Park,
NC. Clinical chemistry measures were performed on an
Olympus AU-640 clinical chemistry analyzer (Beckman Coulter)
using standard enzymatic procedures. The following analytes
were measured: alanine aminotransferase (ALT), aspartate ami-
notransferase (AST), and total bilirubin (TBIL).
Circulating microRNA-122. Plasma levels of miR-122 were assayed
using previously described methods (Kroh et al., 2010). Briefly,
reverse transcription reactions were performed using the TaqMan
miRNA Reverse Transcription Kit and miRNA-specific stem-loop
primers for miR-122 and miR-39 (Applied Biosystems). Standard
curves with known concentrations of miR-122 and miR-39 were
generated in parallel using miScript miRNA mimics (Qiagen).
qPCR was performed on both samples and standards using the
TaqMan Universal PCR Master Mix II with no UNG and miRNA-
specific TaqMan primer/probe mixes (Applied Biosystems) on a
7900HT Fast Real-Time PCR System (Applied Biosystems). Cycle
threshold (CT) values for miR-122 were normalized using CT values
for the spiked-in miR-39 as previously described in Kroh et al.
(2010). Absolute values of miR-122 copy number were determined
using the synthetic miR-122 standard curve.
Histology. Formalin-fixed liver tissue was paraffin-embedded,
cut into 5-mm sections and stained with hematoxylin and eosin
(H&E). H&E stained slides were microscopically examined and
scored by a Board-Certified Veterinary Pathologist (Charles
River Laboratories, Pathology Associates).
Statistical Analysis of Phenotype Data. Descriptive statistics on
quantitative values, including single parameter tests, were
performed using GraphPad Prism statistical software version
6.07. Mean values from body and organ (relative) weight meas-
urements and clinical laboratory tests were compared with
those of control groups using a 2-way analysis of variance.
Comparisons between control and treated animals within a
strain were performed using a Bonferroni posttest. Fold-change
(compared with control) values were calculated for each strain
pair, averaged by strain, and used for comparisons across
strains. A Spearman’s rank correlation was used when compar-
ing the fold change (for each strain pair) of clinical chemistry
analytes to one another or to plasma drug concentration. Group
comparisons for clinical observations and gross and microscopic
pathology data were made using non-statistical methods.
Six animals died prematurely during the study and were
excluded from the analysis of terminal endpoints. All deaths
occurred shortly after the interim blood draw. Subdural hemor-
rhages were noted in 3 of these animals, and it is suspected that
these deaths were accidental. No liver lesions were observed
during histological examination that could account for the early
deaths in any of these animals. Insufficient sample volume,
operator error, or values below the limit of quantitation resulted
in the inability to obtain terminal endpoint values from 13 ani-
mals for ALT and AST, 18 animals for bilirubin, and 12 animals
for miR-122. Plasma drug concentration (parent and metabolite)
values were obtained from all but 2 animals at the interim 2 h
blood draw. One animal (tolvaptan-treated, strain CC057/Unc)
was identified as an outlier in several endpoints and was there-
fore excluded from correlation analysis as well as QTL mapping.
At 24 h, plasma tolvaptan concentrations for many animals
were below the limit of quantitation (1 ng/ml). These were
reported at 1 ng/ml for the purposes of data analysis.
Definitions of Baseline, Postdrug, and Tolvaptan Response Phenotypes
for Regression-based Statistical Modeling. The statistical analysis
sections below use a set of related regression-based models to
infer effects on 3 types of outcome: baseline phenotypes, post-
drug phenotypes, and tolvaptan response phenotypes. Unless
otherwise specified, baseline phenotypes refer to outcomes
measured in vehicle-treated mice (typically after treatment
with vehicle), and postdrug phenotypes refer to outcomes
measured in tolvaptan-treated mice. Tolvaptan response phe-
notypes have a special definition based on the experimental
pairing of tolvaptan- and vehicle-treated mice described earlier.
Formally, we define the ith (matched) pair as comprising 2 mice
of CC strain s½i but of opposite treatment assignment, where
treatment with vehicle or tolvaptan occurred on the same dos-
ing date d½i. Letting yi be the (postdrug) phenotype of tolvaptan-
treated mouse and yi0 be the (baseline) phenotype of its vehicle-
treated pair, the tolvaptan response for pair i was defined as
Di ¼ tðyiÞ  tðyi0 Þ; (1)
where t is a normalizing transformation; in the case of biochem-
istry analytes, t is the loge; such that Di measures the log fold
change between the 2 paired mice. Tolvaptan response pheno-
types have been deposited in the Dryad Digital Repository and
can be downloaded at http://dx.doi.org/10.5061/dryad.ch4p5.
Estimating Tolvaptan Response, Strain-Specific Tolvaptan Response,
and Heritability in the CC. The response in a given phenotype to
tolvaptan treatment across the 45 CC strains was assessed using
the linear mixed model,
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Di ¼ lþ strains½i þ dated i½  þ ei; (2)
where the intercept l estimates the overall effect of tolvaptan
treatment, the random effect strains½i  N 0;r2strain
 
estimates
the strain-specific deviation from this overall effect, and dosing
date and residual error are modeled as random effects dated½i
 N 0; r2date
 
and ei  N 0; r2
 
respectively. Although the
genetic similarity between most pairs of strains was consistent
and low (similarity score of 0.14 on average), similarity between
the 2 lines which shared a breeding funnel was high (0.79).
Since the strain effect term acts as a proxy for overall effects of
genetic background, these lines were modeled as having the
same effect, such that the actual number of strain effects mod-
eled was 44. Models were fitted using the R package lmer (Bates
et al., 2015) and tests for fixed and random effects were con-
ducted using R package lmerTest (Bates et al., 2015). The herit-
ability of the tolvaptan response for the phenotype was defined
as h2 ¼ r2strain=ðr2strain þ r2date þ r2Þ. Heritability estimates are in
general imprecise and reported point estimates for h2 in this
study should be assumed to have wide CIs. Following identifica-
tion of a subgroup of sensitive strains, we fitted an additional
model that controlled for the subgroup to determine how much
strain-specific variation remained, ie,
Di ¼ lþ bsenssensitives i½  þ strains½i þ dated i½  þ ei; (3)
where sensitives i½  is a 01 indicator for the sensitive subgroup,
and bsens is the additional effect of tolvaptan in this subgroup.
Strain-specific effects and heritabilities for baseline and
postdrug outcomes were estimated using linear mixed models
similar to those in Equations (2) and (3) but with Di replaced by
the appropriate individual-level measurement, tðyi0 Þ or tðyiÞ.
Microarray Processing. Total RNA was isolated from the median
lobe liver tissue of all animals using Trizol reagent (Invitrogen)
according to manufacturer’s instructions. The isolated RNA was
further purified using the QIAcube automated system (Qiagen).
Following purification, the quantity of RNA was determined spec-
trophotometrically and the integrity of the RNA was evaluated
with the Agilent 2100 Bioanalyzer. Double-stranded cDNA was
synthesized from 50 to 150 ng (dependent on RNA yield) of total
RNA, then transcribed to biotin-labeled cRNA using the 3’ Express
IVT kit (Affymetrix). Fifteen mg of labeled cRNA was fragmented
and prepared for hybridization on HT MG430 PM peg arrays. The
Gene Titan robotic instrumentation (Affymetrix) was used to per-
form the hybridization, washing and scanning of the peg arrays.
Affymetrix CEL files were normalized using the Robust
Multi-array Average method with log2 transformation (Irizarry
et al., 2003) implemented in Affymetrix Power Tools (APT, v
1.17.0). To avoid confounding from genetic variation (Keane
et al., 2011), probes containing any SNPs in the genome of 45 CC
strains were masked using the “kill-list” option in the APT mod-
ule “apt-probeset-summarize”. A second pre-filtering step was
then performed to eliminate control probe sets, probe sets with-
out mRNA annotation, and lowly expressed probe sets defined
as the maximum of log2 transformed expression level across
samples less than an empirically chosen cutoff of 3.66. Principal
component analysis (PCA) was used to evaluate the overall per-
formance of the arrays and identify outliers. Hierarchical cluster-
ing was then applied using the R function “hclust” with the
average link function. Hierarchical clustering and PCA analysis
indicated that all arrays were highly correlated and there were
no obvious outliers (data not shown). After careful quality con-
trol procedures on probe, probe sets, and samples, the dataset
for primary analyses consisted of 23 384 probe sets representing
13 878 genes, which is approximately equal to the number of
genes expressed in the liver (Fagerberg et al., 2014; Yu et al., 2010).
Statistical Analysis of Gene Expression Data. Two complementary
approaches were used on the gene expression data. First, to
identify transcripts correlated ALT fold change, a simple linear
regression analysis was performed to regress ALT fold change
values on fold change in gene expression. Second, to identify
transcripts differentially expressed with treatment (tolvaptan
vs vehicle) and response to tolvaptan (sensitive vs resistant
strains), a linear mixed model was used to analyze expression
differences between tolvaptan- and vehicle-treated pairs of
mice (explained below), while accounting for dependencies
among biological replicates of each strain.
The contribution of CC strains, scan date, dosing date, and
error to variability in expression data was examined first. The
variabilities explained by each term were similar in the 2 treat-
ment groups across probe sets. In tolvaptan-treated mice, the
mean variabilities across probe sets were explained by error
(61%), followed by strain (29%), scan date (9%), and dosing date
(0.9%). Similarly, in vehicle-treated mice, the mean variabilities
in expression values across the probe sets were explained by
error (66%), followed by strain (24%), scan date (9%), and dosing
date (1%). This result suggests that scan date and dosing date
together contributed 10% of the variability in expression levels
and hence needed to be adjusted accordingly.
Next, batch effects from scan date and dosing date were
regressed out using a linear model, and the residuals were used to
test for expression differences between tolvaptan- and vehicle-
treated pairs. For a given probe set, lettingDi be the expression dif-
ference for the ith pair, we fitted the linear mixed model
Di ¼ lþ strains½i þ ei; (4)
with other terms as described by Equation (2). The effect of tol-
vaptan on expression was estimated as intercept l and p-values
for this parameter were calculated using the t-test with
Satterthwaite approximations to the degrees of freedom using R
package lmerTest (Bates et al., 2015).
A tolvaptan-induced difference in expression is not necessa-
rily relevant to liver toxicity. To assess this relevance for each
probe set, we compared the fit of Equation (4) with that of a
model including an indicator for the sensitive strains (as in
from Equation 3), ie,
Di ¼ lþ bsenssensitives i½  þ strains½i þ ei; (5)
whereby significant improvement in fit supports relevance. The
p-values for this comparison were based on an F-test with
Kenward-Roger approximation using R package pbkrtest
(Halekoh and Højsgaard, 2014). To correct for multiple statistical
comparisons, we applied the Benjamini-Hochberg false discovery
rate (FDR)-controlling procedure (Benjamini and Hochberg, 1995).
Pathways enriched among statistically significant, differen-
tially expressed genes in the data were identified using the Tox
Analysis module in Ingenuity Pathway Analysis (Ingenuity
Systems; Build version 366632M; Content version: 24718999).
Gene expression data generated for this manuscript can be
downloaded in its entirety from the Gene Expression Omnibus
repository under the accession number GSE83739. All data are
MIAME compliant.
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Genotyping and Haplotype Reconstruction of the CC Mice. The
genome of each CC strain comprises a mosaic of segments, or
haplotypes, inherited from the 8 CC founders. Genotyping of the
strains is followed by inference of the underlying haplotype
mosaic, which is then used in the detection of QTL. Genotyping
was performed using MegaMUGA, a custom 78K-marker array
built on the Illumina Infinium genotyping platform; it has been
designed to support the CC, and is optimized to identify founder
contributions, and to detect any residual heterozygosity
(Morgan and Welsh, 2015). Probe intensities from MegaMUGA
were then converted using a hidden Markov model (HMM) (Fu
et al., 2012) into a probabilistic representation of the haplotype
mosaic: for each strain at each genotyped locus, the HMM calcu-
lates the probability of having inherited each of the possible
haplotype pairings (diplotype), giving rise to 36 diplotype proba-
bilities. The diplotype probabilities for 45 CC lines used in these
experiments had been calculated previously and were down-
loaded from the CC status website (http://csbio.unc.edu/
CCstatus/index.py?run¼AvailableLines; last accessed January 4,
2017). The 77K markers on the genome were reduced to the 7767
genome segments for faster analyses and reduction of genotyp-
ing errors by averaging the probability matrices of 10 markers to
create a new matrix for each segment. Genome scans were com-
parable using 77K markers versus 7767 segments, supporting the
averaging across markers. All genomic locations were reported
using NCBI mouse genome build 37.
General Statistical Model for QTL and eQTL Mapping. QTL mapping
was performed by testing the association between tolvaptan
response and the inherited founder haplotypes at each point in
the genome. Genetic association was tested at each genomic
locus by first fitting a null model for tolvaptan response that
included effects of strain and dosing date, and then fitting an
alternative model that included a QTL additive effect based on
the haplotype reconstruction at the locus. Comparison of these
2 models produced scores of association across the genome
(genome scans) for which genome-wide significance thresholds
were then calculated. These 2 models are described in detail
below.
The null model included random effects of strain and dosing
date, and was identical to that used to estimate heritability
(Equation 2). Note that our use of the strain random effect is
equivalent to a polygenic (or kinship) effect that models all CC
strains as equally related, which they approximately are. Note
also that a covariate for body weight was not included since
weights between each pair were similar by design. The alterna-
tive model for locus m on the ith pair’s tolvaptan response Di
was equivalent to the null model with an additional term,
Di ¼ lþ QTLs½i;m þ strains½i þ dated½i þ ei; (6)
where the QTL contribution QTLsm represents the sum of the
effects of the founder haplotypes, weighted by haplotype count
for individual i at locus m. For strain s this quantity is defined as
QTLsm ¼ bAJ;mxAJ;sm þ    þ bWSB;mxWSB;sm (7)
where, eg, bAJ;m is the effect of the AJ haplotype on tolvaptan
response, and xAJ;sm is the number of founder AJ haplotypes
present at locus m in CC strain s. However, since the haplotype
counts xAJ;sm; . . . ; xWSB;sm are not observed directly, being
approximated only via the diplotype probabilities and therefore
subject to uncertainty, we modeled QTLsm using 1 of 2
approximations: for QTL mapping, that is, mapping of nontran-
script phenotypes, we used a new, computationally demanding
method that accounts for haplotype uncertainty; for eQTL map-
ping, we used an existing approach that does not account for
uncertainty but is computationally efficient for large scale anal-
yses. These are described below.
QTL Mapping Using Multiple Imputation and Genome Permutation.
For QTL mapping of nontranscript phenotypes, the QTL model
in Equations (2) and (6) was fitted using a new method based on
multiple imputations (MIs). This new method is closely related
to previous methods used for multiparent populations (Mott
et al., 2000) but incorporates additional steps to take into
account that the haplotype counts in Equation (7) are subject to
uncertainty following Zhang et al. (2014) and references therein
and also Sen and Churchill (2001). At each locus m, the diplotype
probabilities were used to generate I¼50 imputed datasets, that
is, datasets in which all of the diplotype assignments, and
therefore the haplotype counts, were treated as known. For
example, if the 36 diplotype probabilities for strain s were
pAJ;AJ; pAJ;B6; . . . ; pPWK;WSB; pWSB;WSB, then a dataset with the hap-
lotype count xAJ;sm ¼ 2, which corresponds to the homozygote
AJ diplotype, would be imputed with probability pAJ;AJ. Each
imputed dataset was then used to fit the QTL model in
Equations (2) and (6). This fitted model was then compared
against the null model using a likelihood ratio test (LRT), leading
to a log10(p) score (the negative log10 of the uncorrected p-
value from the LRT). These imputed log10(p)’s were then aggre-
gated, with their median being used as the final reported
log10(p) for locus m. This was repeated for all loci to produce a
genome scan.
Genome-wide significance thresholds were calculated using
a permutation procedure designed to control family-wide error
rate, also developed specifically for this study. At each permuta-
tion, the genome scanning procedure described above was
repeated but with the genome information of strains
1; 2; . . . ; 43;44 having been reassigned to a random reordering of
those strains, eg, 28;41; . . . ; 13; 7; from this genome scan, the
maximum -log10(p) was then recorded. The maximum log10(p)
for all permutations was used to fit a generalized extreme value
distribution (Dudbridge and Koeleman, 2004), and the upper
fifth percentile of this fitted distribution was taken as the 0.05
genome-wide significance threshold.
eQTL Mapping Using Regression on Probabilities and FDR. QTL map-
ping of transcript abundance (eQTL mapping) was performed
using an approximation for the QTL contribution described pre-
viously in Mott et al. (2000) and referred to here as regression on
probabilities (ROPs) after Zhang et al. (2014). Briefly, in ROP, the
haplotype counts in Equation (7) are substituted by their expect-
ations based on the diplotype probabilities, such that, for exam-
ple, xAJ;sm ¼ 2pAJ;AJ þ
P
f 6¼AJpAJ;f where f indexes the founders.
Unlike MI, this approximation does not account for uncertainty,
however, it also does not require I model fittings per locus, and
thus is considerably faster and scalable. The log10(p) for each
locus was calculated from an LRT of the null versus alternative
model, and for scalability, thresholds were based on the FDR
(Benjamini and Hochberg, 1995). For “targeted” eQTL mapping
where we examined all eQTLs within the region of 6 10 Mb
around 80% CI of the QTL peak, we calculated FDR from p-values
of the most significant eQTL for each probe set within the tar-
geted region.
As reported in many eQTL studies, there are 2 distinct types
of expression associations: local eQTL (cis) and distal eQTL
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(trans). Following Rockman and Kruglyak (2006), the terms local
eQTL and distal eQTL were used. Local eQTL was defined as
segment-transcript pairs in the range of 10 Mb upstream and
downstream of the physical location of the target transcript.
Distal eQTLs included all the segment-transcript pairs outside
the local region.
Haplotype Effects at Detected QTL and CIs for QTL Location. For
detected QTL we estimated the effect of alternate haplotype
substitutions on drug response using the Diploffect model of
Zhang et al. (2014). This is a Bayesian linear mixed model that
provides CIs (as highest posterior density intervals) both for
additive (haplotype) effects and dominance (heterozygous dip-
lotype) effects, incorporating any uncertainty in the haplotype
assignments from the HMM.
CIs for the location of detected QTL were defined using posi-
tional bootstrapping after Visscher et al. (1996), as previously
described by Phillippi et al. (2014) and Woods et al. (2012). To pro-
vide estimates that are computationally stable, 1000 bootstraps
were performed for each QTL and the 80% CI was reported.
Testing of Candidate SNPs via Merge Analysis. To perform a merge
analysis (Yalcin et al., 2005) on segregating SNPs within the 80%
CI of QTL on chromosome 14, whole-genome sequencing data
(release 1410) was downloaded from the Wellcome Trust Sanger
Institute’s Mouse Genomes Project (http://www.sanger.ac.uk/
resources/mouse/genomes/; last accessed January 4, 2017). Prior
to the merge analysis, filtering was performed to remove SNPs
with poor variant calling, more than 1 alternative allele, and
noninformative strain distribution patterns across the 8 CC
founder strains (eg, all 8 founder strains have the same allele).
At each variant within the 80% CI, p-values from the 2-allele
merged model were compared with those from the 8-allele hap-
lotype model to evaluate how well genotypic variation at each
SNP represented by strain distribution pattern correlates with
the phenotypic distribution and whether the correlation is
stronger than that seen in the 8-allele model.
Circulating Secretory Leukocyte Peptidase Inhibitor. Levels of circu-
lating secretory leukocyte peptidase inhibitor were assayed in
the remaining plasma of the 3 sensitive strains (CC033/
GeniUnc, CC057/Unc, CC065/Unc) and 2 resistant strains (CC012/
GeniUnc and CC027/GeniUnc) using an ELISA (Cloud-Clone
Corp.). No plasma was remaining for 1 tolvaptan-treated animal
in strain CC033/GeniUnc. One animal (tolvaptan-treated, strain
CC065/Unc) was identified as an outlier (Grubbs’ test, a¼0.05)
and was therefore excluded from statistical analyses. Statistical
analyses were performed using GraphPad Prism statistical soft-
ware version 6.07. Fold-change (compared with control) values
were calculated for each strain pair, averaged by strain, log2
transformed, and used for comparisons across strains. Fold-
change values were also log2 transformed, averaged by the
responses, and compared using a Student’s t-test. A Spearman’s
correlation was used when comparing the fold change (for each
strain pair) of analytes (without transformation) to one another.
RESULTS
Tolvaptan Induces Plasma ALT Elevations in Sensitive CC Strains
Overall, the single dose (100 mg/kg) of tolvaptan was well toler-
ated across all CC strains. Tolvaptan-related clinical findings were
minimal and consisted mainly of moderate dehydration, an
expected pharmacological effect of the drug (Miyazaki et al., 2007).
No gross findings were observed consistently in the livers of
tolvaptan-treated animals in any strain, and no statistically sig-
nificant differences in the liver-to-body weight ratio were
observed between tolvaptan- and vehicle-treated animals at nec-
ropsy (p>.05, Bonferroni posttest). No histological changes in the
liver were associated with tolvaptan treatment in any strain.
However, statistically significant elevations in serum ALT levels
in tolvaptan-treated animals relative to vehicle-treated controls
were observed in 3 of the 45 strains (Figure 1A). These strains had
the highest mean fold change in ALT between tolvaptan-treated
animals and their paired, vehicle-treated controls (Figure 1B). ALT
fold change was significantly correlated with changes in plasma
AST (Spearman r¼0.6528, p<.0001), TBIL (Spearman r¼0.2626,
p¼.0009), and miR-122 (Spearman r¼0.3202, p<.0001) supporting
that the ALT elevations reflect subclinical liver toxicity. A correla-
tion matrix for all phenotypic variables is shown in Figure 2.
For each of ALT, AST, TBIL, and miR-122, linear mixed mod-
eling was used to examine how tolvaptan response, the log fold
change between matched vehicle- and drug-treated mice, var-
ied with genetic background. Tolvaptan response was parti-
tioned into an overall effect, constant across strains, and a set
of strain-specific effects, collectively representing the heritable
component of vulnerability to DILI. Next, the amount of herit-
ability that remained after controlling for the group of 3 sensi-
tive strains and the magnitude of this sensitive group effect was
examined. Last, heritability of drug response was compared
with heritability of the phenotype at baseline, as estimated
from the vehicle-treated mice. These comparisons are summar-
ized below, with full results in Supplementary Tables 1–3.
FIG. 2. Correlation matrix representing relationships between phenotypic varia-
bles analyzed in tolvaptan-treated CC mice. Phenotypic variables are plotted
against themselves and other variables on the x- and y-axes. Shading intensity
of the corresponding squares reflect the Spearman correlation coefficient, r.
Diagonal lines within the squares reflect the directionality of the correlation (ie,
lines going from bottom left corner to top right corner indicate positive correla-
tion; lines from top left corner to bottom right corner indicate negative
correlation).
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For ALT, the overall effect of tolvaptan on fold change was
only borderline significant (p¼.06), but the effect of CC strain
was highly significant (p¼2.3E-4), explaining 27% of the var-
iance. Most of this heritability of tolvaptan response could be
explained by the grouping of 3 sensitive and 42 nonsensitive
strains (where 2 of the nonsensitive strains were modeled as
having the same effect owing to their high genetic similarity, as
described in Materials and Methods section); after controlling
for the sensitive group, the effect of CC strain was insignificant
(p¼.49). For AST, the overall effect of tolvaptan on fold change
was a little stronger (p¼.01) with slightly less explained by CC
strain (18%, p¼.02); but as with ALT, this heritability was insig-
nificant after controlling for the sensitive strains (p¼.49).
Notably, although baseline levels of ALT and AST were heritable
(ALT 38%, p¼9.2E-8; AST 34%, p¼4.2E-6), they were not predic-
tive of tolvaptan response in their matched pairs.
The effect of tolvaptan on TBIL fold change was highly sig-
nificant overall (p¼4.7E-5), but the effect of CC strain was not
significant (p¼.12), explaining 12% of the variance; baseline TBIL
was also not significantly heritable across the CC strains (2.6%,
p¼.72). In contrast, the effect of tolvaptan on miR-122 fold
change was insignificant, both overall and across CC strains;
this was despite baseline miR-122 being significantly heritable
(20%; p¼5E-3). In general, heritable effects on baseline measures
were not predictive of heritable effects on drug response, nor
vice versa.
Plasma Tolvaptan Concentration Varies by Strain but Is Correlated
With ALT
To determine whether the strain-dependent variability in
plasma ALT levels was related to drug exposure, plasma tolvap-
tan levels were measured at 2 and 24 h postdose. Mean plasma
tolvaptan concentrations at 2 h ranged from 301 to 3719 ng/ml
(Figure 1C). Tolvaptan plasma concentrations at 2 h were not
significantly correlated with ALT fold change in the correspond-
ing pairs (Spearman r¼0.1060, p¼.1809). By 24 h, the concentra-
tion had decreased in all strains (range: 1–694 ng/ml), with many
strains having values below the limit of quantitation (Figure 1D);
nonetheless, correlation of these values with ALT fold change in
the corresponding pairs was significant (Spearman r¼0.3053,
p<.0001). At both 2 and 24 h, tolvaptan concentration showed
strain-specific variation, giving heritability estimates of 37%
(p¼3.1E-7) and 27% (p¼1.9E-4) respectively, these being only
slightly reduced when controlling for the sensitive strain group to
33 and 21%, respectively (Supplementary Table 3).
Plasma concentrations of a significant human metabolite of
tolvaptan, DM-4103, were also measured. Plasma DM-4103 con-
centrations at 2 h were not significantly correlated with plasma
tolvaptan concentrations at 2 h (Spearman r¼0.1204, p¼.1106)
or with ALT fold change values in the corresponding pairs
(Spearman r¼0.07457, p¼.3472). Plasma DM-4103 concentrations
at 24 h were weakly correlated with plasma tolvaptan concen-
trations at 2 h (Spearman r¼0.1514, p¼.0481) and strongly corre-
lated with plasma tolvaptan concentrations at 24 h (Spearman
r¼0.4267, p<.0001). However, plasma levels of DM-4103 at 24 h
were not correlated with ALT fold change in the corresponding
pairs (Spearman r¼0.03979, p¼.6152). Plasma drug concentrations
are included among the variables represented in the correlation
matrix shown in Figure 2. The heritability of DM-4103 concentra-
tion among the CC strains was estimated at 24% for both time
points and was not meaningfully changed by controlling for the
sensitive strain group (Supplementary Tables 1–3).
Tolvaptan-Induced ALT Elevation Is Most Associated With Genetic
Variation on Chromosome 14
Genetic mapping was used to identify genomic regions whose
variation might underlie the strain-dependent variability in ALT
fold change, and more generally tolvaptan-induced liver
response. Several potential QTL were found to be associated
with ALT fold change at varying levels of significance (Figure 3A).
Although none reached the strict permutation-based threshold
of 8.11 for a genome-wide error rate of a¼0.05, the strongest
association (termed ALT1), and the one that best explained the
strain-specificity, was found on chromosome 14. Founder strain
probabilities at the ALT1 peak (chromosome 14 at 59.47 Mb, nom-
inal log10(p)¼6.41) show an overrepresentation of C57BL/6J DNA
among the pairs of mice with the greatest ALT elevations in
response to tolvaptan (Figure 3B). Bayesian modeling of the QTL
estimated a strong positive effect of the C57BL/6J haplotype on
ALT elevation (Figure 3C). ALT1 was mapped to an 80% CI of
12 Mb (58.27–69.85 Mb) (Figure 3D). This region was interrogated
further to identify quantitative trait genes (QTGs) that may
explain the liver response.
Merge Analysis Identifies Candidate QTGs in QTL on Chromosome 14
Initially, candidate causal variants were identified using merge
analysis (Phillippi et al., 2014; Vered et al., 2014; Yalcin et al.,
2005). Merge analysis compares the significance of association
for individual variants obtained from the haplotype model used
for genome-wide analysis to those obtained using a biallelic
model, where the founder strain haplotypes are “merged” into 2
groups for each biallelic SNP. For potentially causative variants,
both models will explain a significant portion of the variation,
but the biallelic model will do so with far fewer parameters,
thus providing a more parsimonious fit. In the ALT1 region on
chromosome 14 (58.27–69.85 Mb), 753 variants were identified
having a log10(p) from merge analysis greater than log10(p)
from MIs and a log10(p) from merge analysis >5 (Figure 4A). All
753 variants meeting these criteria reflected only 1 strain distri-
bution pattern: C57BL/6J discordant from all other founder
strains (Figure 4B). In total, 33 unique genes were represented
among the 753 variants identified by merge analysis (Table 1).
Three genes have human orthologs, are expressed in the liver,
and have been associated with liver injury and are thus consid-
ered priority candidate QTGs for further investigation: Ephx2
(soluble epoxide hydrolayse), Scara3 (scavenger receptor class A,
member 3), and Zfp395 (zinc finger protein 395).
Fold change in the other measured plasma chemistries were
also used for QTL mapping to see if additional risk factors could
be identified using biomarkers with different mechanisms of
release and/or kinetics. Not surprisingly, the highly correlated
AST also produced a suggestive QTL (log10(p)>4) on chromo-
some 14 (peak at 61.81 Mb, log10(p)¼4.70), but no suggestive
QTLs were observed with TBIL or miR-122 (data not shown).
Expression QTL Mapping Is Used to Identify Additional QTGs
Associated With Sensitivity to the Tolvaptan-Induced Liver Response
The identification of candidate QTGs using phenotype-based
QTL mapping alone is founded on the assumption that a gene
variant (ie, a SNP) causes a change in the protein-coding region
of a gene that ultimately affects the drug response. However,
recent studies have highlighted the importance of variants that
influence responses by regulating gene expression. To explore
these relationships, phenotypic data can be evaluated in the con-
text of gene expression data from the target organ. This approach
has been used successfully in CC mice to identify new candidate
genes for asthma (Kelada et al., 2014; Rutledge et al., 2014). A similar
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approach was applied here to identify additional QTGs. Microarray
profiling was performed using liver tissue of all vehicle- and
tolvaptan-treated animals included this study. Whole genome
expression QTL (eQTL) mapping was performed using expression
values from vehicle- and tolvaptan-treated mice separately. More
importantly, gene-by-environment, or in the case of this study,
gene-by-treatment (GxT) eQTLs were identified using the fold
change (delta) in expression between strain pairs of vehicle- and
tolvaptan-treated mice. A complete description of the overall eQTL
mapping findings is described in the Supplementary material.
Findings, as they relate to QTGs for susceptibility to the tolvaptan-
induced liver response, are described below.
Initially, a “targeted approach” was used to identify addi-
tional QTGs associated with the tolvaptan liver response.
Similar to Kelada et al. (2014) and Rutledge et al. (2014), inquiry
focused on local eQTLs (segment-probe set pairs) within the
region of the phenotype QTL (in this case, the QTL termed
ALT1). Unlike those approaches, however, which focused on
eQTLs present in treated mice only (Kelada et al., 2014; Rutledge
et al., 2014), our analysis was performed using GxT eQTLs, which
are more directly relevant for identifying gene variants that
influence treatment-induced responses. As described in the
Supplementary material, the most significant GxT eQTLs were
distal. Even with a targeted approach designed to increase
statistical power, no local GxT eQTLs in the region of ALT1
passed the threshold for statistical significance (FDR p<.001).
As mentioned earlier, liver gene expression analysis after an
acute, high-dose exposure can also be used to identify activation
of molecular phenotypes that may indicate sensitivity toward an
adverse drug response in humans (Laifenfeld et al., 2014; Leone
et al., 2014). In the absence of overt injury, molecular phenotypes
can be used to identify variants influencing individual
treatment-induced responses. To investigate this possibility,
genome-wide GxT interaction eQTLs (both local and distal) were
examined to identify new molecular phenotypes as well as var-
iants influencing their response. No local GxT interaction eQTLs
were observed. However, 385 distal eQTLs were identified (FDR
p<.001). These eQTLs comprise 14 unique probe sets comprising
11 genes (Table 2). Four of these genes have human orthologs
expressed in the liver with biological relevance to DILI and thus
are considered candidate QTGs for further investigation: Angptl4
(angiopoietin-like 4), Irf3 (interferon regulatory factor 3, Itgb5
(integrin, beta 5), and Mff (mitochondrial fission factor).
Gene Expression Profiling Also Identifies Mechanisms Associated
With the Tolvaptan-Induced Liver Response
Finally, gene expression data were analyzed to provide insight
into mechanisms of toxicity associated with the tolvaptan-
FIG. 3. Genetic mapping using ALT fold change identifies significantly associated locus on chromosome 14. A, Genome scan plot illustrating QTL associated with tol-
vaptan-induced ALT fold change. Dashed horizontal lines indicate genome wide significance at the 0.01, 0.05, and 0.1 levels. An arrow points to the genomic interval
with the highest LOD score (Marker: JAX00381082, Chr14: 59.47 Mb). B, Founder strain probabilities at the locus peak. The x-axis plots paired animals in order from left
to right by increasing ln(ALT fold change). Each horizontal row indicates the probability of a given CC founder haplotype being present at the locus, with darker inten-
sities indicating higher probabilities (0–1.0). C, Estimates and CIs for haplotype substitution effects at the peak locus. D, CI plot for the QTL on chromosome 14. The 80%
CI (Chr14: 58.27–69.85 Mb) is spanned by black bars.
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induced liver response. Three different analytical approaches
were used. First, a regression analysis was performed using the
fold change in gene expression for each probe set on the array and
fold change in ALT. Tolvaptan-induced changes in 1020 probe sets
were significantly correlated with tolvaptan-induced changes in
ALT (FDR p<.2). The top pathway enriched among these genes,
and a second pathway in the top 10, are associated with the regu-
lation of bile acid homeostasis: “FXR/RXR Activation” and “Bile
Acid Biosynthesis” (Figure 5A). Second, transcripts differentially
expressed with treatment (tolvaptan vs vehicle) were identified
using a linear mixed effect model as described in the methods. A
total of 250 probe sets were differentially expressed with tolvap-
tan treatment across all strains (FDR p<.2). Included in the top 10
pathways enriched among these genes are pathways associated
with immune response: “Acute Phase Response Signaling”,
“Chemokine Signaling”, and “CXCR4 Signaling” and oxidative
stress: “Nrf2-meidated Oxidative Stress Response” (Figure 5B).
Last, all strains were categorized as “sensitive” or “resistant” based
on tolvaptan-induced elevations in ALT, and transcripts differen-
tially expressed with response (sensitive vs resistant strains) were
identified using a linear mixed effect model as described in the
methods. This approach identified 449 tolvaptan-responsive probe
sets differentially expressed between sensitive and resistant
strains (FDR p<.2). The top pathway enriched among these genes
is associated with the regulation of bile acid levels within the hep-
atocytes: “FXR/RXR Activation” (Figure 5C).
Overlap of Treatment and Response Associated Genes Identifies
Individual Transcripts That May Contribute to the Tolvaptan-
Induced Liver Response in CC Mice
Two probe sets were found to be significantly differentially
expressed with both treatment and response (FDR p<.2) and
have a fold change>j2j associated with both factors. These
probe sets corresponded to the genes: Slpi (secretory leukocyte
peptidase inhibitor) and Wfdc12 (whey acidic protein 4-disul-
fide-core 12) (Figure 6). Both genes play a similar role in modu-
lating inflammation (Glasgow et al., 2015; Odaka et al., 2003;
Reeves et al., 2013; Williams et al., 2006) and the more exten-
sively studied Slpi has been shown recently to be elevated in liv-
ers of patients with acetaminophen-induced acute liver failure
(AALF) (Antoniades et al., 2014). In these patients, elevated tran-
script levels corresponded to elevations in Slpi protein, both in
liver tissue and in circulation. To see if this was also true in the
CC mice, Slpi levels were measured in plasma from the 3 sensi-
tive strains (demonstrating elevated Slpi transcript levels) as
well as 2 resistant strains (with no increase in Slpi transcript).
Circulating Slpi was consistently elevated in the sensitive
strains (Figure 7A) and the average fold change in sensitive
strains was significantly higher than the average fold change in
resistant strains (Figure 7B). Fold change in circulating Slpi was
also correlated with fold change in ALT (Spearman r¼0.6883,
p¼.0016), and fold change in Slpi transcript levels in the liver
(Spearman r¼0.6526, p¼.0025).
FIG. 4. Merge analysis of chromosome 14 QTL identifies candidate causal variants. A, Comparison of log10(p) values from 8-allele haplotype model (lines) to log10(p)
values from 2-allele merge analysis (dots) for variants in Chr14: 58.27–69.85 Mb with a log10(p) from merge analysis >2. Dark dots indicates variants with a log10(p)
from merge analysis >log10(p) from 8-allele haplotype model and a log10(p) from merge analysis >5. B, Corresponding strain distribution pattern for variants repre-
sented in A. Each track corresponds to strain distribution pattern indicated in the left margin by a string of 0’s and 1’s representing the alleles for the 8 founder strains,
in the order: A/J, C57BL/6J, 129S1Sv/ImJ, NOD/ShiLtJ, NZO/H1LtJ, CAST/EiJ, PWK/PhJ, and WSB/EiJ. Within each SDP track, the vertical lines indicate the locations of the
variants within the strain distribution pattern.
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DISCUSSION
The design of this study exploits 2 key features of the CC pop-
ulation: (1) the ability to repeatedly measure phenotypes
under drug- and vehicle-treatments that were randomized
between genetically identical, matched mouse pairs; and (2)
the ability to observe these phenotypes across a diverse and
equally related set of genetic backgrounds. This combination
of features allows rigorous estimation of the causal effect of
drug treatment, where the tolvaptan response defined by each
pair is confounded by neither baseline outcomes nor genetic
background. Additionally, these features provide a stable basis
for detecting GxT effects and replicating them in follow-up
studies. By comparison, the use of a single inbred strain
provides replicability and rigor but no genetic diversity and
hence no power. On the other end of the spectrum, the use
of outbred resources such as the Diversity Outbred popul-
ation provides genetic diversity and high mapping resolution
TABLE 1. Candidate Quantitative Trait Genes Identified by Merge Analysis
Gene Symbol Gene Name Human Orthologue Liver Expression Biological Relevance
4930438E09Rik RIKEN cDNA 4930438E09 gene  NA NA
Adam2 A disintegrin and metallopeptidase domain 2 þ  NA
Adam28 A disintegrin and metallopeptidase domain 28 þ  NA
Adam7 A disintegrin and metallopeptidase domain 7 þ  NA
Adra1a Adrenoceptor alpha 1A þ þ 
Bnip3l BCL2/adenovirus E1B 19kDa interacting protein 3-like þ þ 
Cdca2 Cell division cycle associated 2 þ  NA
Dock5 Dedicator of cytokinesis 5 þ þ 
Dpysl2 Dihydropyrimidinase-like 2 þ þ 
Ebf2 Early B-cell factor 2 þ  NA
Elp3 Elongator acetyltransferase complex subunit 3 þ þ 
Ephx2a Epoxide hydrolase 2, cytoplasmic þ þ þ
Fbxo16 F-box protein 16 þ þ 
Fzd3 frizzled homolog 3 þ þ 
Gm10032 Predicted gene 10032  NA NA
Gm10860 Predicted gene 10860  NA NA
Gm20667 Predicted gene 20667  NA NA
Gm23899 Predicted gene 23899  NA NA
Gm24258 Predicted gene 24258  NA NA
Gm27647 Predicted gene 27647  NA NA
Gm6878 Predicted gene 6878  NA NA
Kctd9 Potassium channel tetramerization domain containing 9 þ þ 
Mir6539 MicroRNA 6539 – NA NA
Nuggc Nuclear GTPase, germinal center associated þ þ –
Pnma2 Paraneoplastic antigen MA2 þ  NA
Pnoc Prepronociceptin þ  NA
Ppp2r2a Protein phosphatase 2, regulatory subunit B, alpha þ þ 
Ptk2b PTK2 protein tyrosine kinase 2 beta þ þ 
Scara3a Scavenger receptor class A, member 3 þ þ þ
Scara5 Scavenger receptor class A, member 5 þ þ 
Spata13 Spermatogenesis associated 13 þ þ 
Stmn4 Stathmin-like 4 þ  NA
Zfp395a Zinc finger protein 395 þ þ þ
aIndicates priority candidate QTGs based on meeting all 3 criteria: human ortholog, liver expression, and biological relevance.
TABLE 2. Candidate Quantitative Trait Genes Identified by Whole Genome Gene by Treatment eQTL Mapping
Gene Symbol Gene Name Human Orthologue Liver Expression Biological Relevance
Angptl4a Angiopoetin-like 4 þ þ þ
Cpne1 Copine 1 þ þ 
Hist1h2be Histone Cluster 1, H2be þ  NA
Htra1 HtrA Serine Peptidase 1 þ þ 
Irf3a Interferon regulatory factor 3 þ þ þ
Itgb5a Integrin, Beta 5 þ þ þ
Lrrtm3 Leucine rich repeat transmembrane neuronal 3 þ  NA
Mffa Mitochondrial fission factor þ þ þ
Rarres1 Retinoic acid receptor responder 1 þ þ 
Slc7a6 Solute Carrier Family 7, member 6 þ  NA
Sox9 Sex determining region Y box 9 þ þ 
aIndicates priority candidate QTGs based on meeting all 3 criteria: human ortholog, liver expression, and biological relevance.
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FIG. 5. Ingenuity pathway enrichment analysis of liver gene expression identifies general mechanisms associated with the tolvaptan-induced liver response. Top 10
pathways enriched among gene expression changes associated with A, ALT fold change B, tolvaptan treatment, and C, tolvaptan response (sensitive vs resistant
strains). Significant probe sets (FDR p<.2) were identified by a regression analysis in A or linear mixed model in B and C. Pathway significance is plotted by log10(p) on
the left y-axis and represented by the black bars on the graphs. The dashed line indicates a log10(p) >1.3 threshold for significance. The ratio of significant genes rela-
tive to the total genes in the pathway is plotted on the right y-axis and represented by the gray dots (connected by a gray line) on the graphs.
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(Svenson et al., 2012), but cannot support such a rigorous
measurement of treatment response nor provide a stable basis
for replication studies, follow-up mechanistic studies, or test-
ing next-in-class compounds.
After a single dose of tolvaptan only 4 the daily human
equivalent dose used in the ADPKD clinical trials (Watkins et al.,
2015), evidence for liver stress was observed in 3 CC strains. This
finding was unexpected, given that no liver injury was observed
FIG. 6. Gene expression changes in Slpi and Wfdc12 are associated with tolvaptan treatment and liver response. Average fold change for each strain pair is plotted by
response on the top and strain (for the 3 sensitive strains) on the bottom for A, Slpi and B, Wfdc12. Both probe sets were significantly associated with treatment and
response (FDR p<.2, FC>2).
FIG. 7. Slpi protein is elevated in plasma of sensitive strains. A, Average log2(fold change) by strain for strain pairs from 2 resistant and 3 sensitive strains. Arrow points
to outlier pair in sensitive strain CC065/Unc (Grubbs’ test, a¼0.05) that was removed prior to statistical analysis in B. B, Average log2(fold change) by response (with out-
lier from A removed). **p<.01 indicates the difference between sensitive and resistant strains (Student’s t-test).
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in traditional nonclinical models after multiple treatments with
higher doses (Oi et al., 2011). This rapid response at a relatively
low dose suggests that these 3 CC strains may be more geneti-
cally sensitive to a tolvaptan-induced liver response than other
CC strains and traditional mouse models.
Variation in plasma tolvaptan exposure explained <10% of
variability in ALT values observed across animals in this study.
This is consistent with the lack of an obvious relationship
between tolvaptan exposure and hepatotoxicity in subjects
from the tolvaptan clinical trials (Watkins et al., 2015). As a
result, genetic variants that may contribute to this sensitivity in
mice were explored further using ALT fold change as a marker
of the liver response and a QTL was identified on chromosome
14. To further ensure this QTL was not simply the result of expo-
sure, genetic mapping was also performed using plasma con-
centrations of tolvaptan and DM-4103 at 2 h and no suggestive
peaks (log10(p)>4) were observed (data not shown).
Furthermore, mapping was also performed using ALT fold
change with plasma concentration of tolvaptan or DM-4103 as a
covariate, and the most significant QTL was still on chromo-
some 14.
Three priority candidate QTGs identified via merge analysis
have biological relevance to liver injury. Ephx2 is a liver enzyme
that catalyzes the conversion of protective epoxyeicosatrienoic
acid to dihydroxyeicosatrienoic acid, which is associated with
increased hepatic inflammation and injury (Schuck et al., 2014).
Scara3 is a cellular stress response protein that has been shown
to protect cells, including hepatocytes, from oxidative stress by
scavenging reactive oxygen species (Oguro et al., 2014). Zfp395,
the mouse ortholog of human zinc finger protein 395 (ZNF395),
is a hypoxia-inducible transcription factor that contributes to
inflammation by superactivating proinflammatory cytokines
(Herwartz et al., 2015). Associations of DILI risk with these genes
may suggest a role for oxidative stress and/or inflammation in
the tolvaptan liver response.
In addition to using traditional phenotypes for QTL mapping,
whole-genome eQTL mapping was performed to identify drug-
induced molecular phenotypes that are influenced by genetic
variation. Genes with drug-induced eQTLs may influence the
drug response and can inform potential mechanisms of toxicity
as well as genetic risk factors for toxicity susceptibility. Four
genes that may mediate or modulate a DILI response were iden-
tified using drug-induced fold change in gene expression as the
primary phenotype. Angptl4 controls inflammation and apopto-
sis in the liver (Guo et al., 2015). Irf3 regulates cytokine levels
and plays a role in liver diseases such as steatosis, inflamma-
tion, and alcoholic liver injury (Loi et al., 2013; Ni et al., 2015).
Itgb5 is a subunit of an integrin receptor involved in cell adhe-
sion, viral entry, and antigen processing (Lyle and McCormick,
2010). Mff2 controls mitochondrial and peroxisomal fission, an
important process affecting mitochondrial adaptation and
apoptosis (Gandre-Babbe and van der Bliek, 2008). Alterations in
these genes may suggest a role for immunotoxicity and/or mito-
chondrial dysfunction in the tolvaptan liver response.
Gene expression profiling was also used to gain mechanistic
insight into the tolvaptan liver response. Pathways most
enriched among genes associated with tolvaptan-induced ALT
elevations included “FXR/RXR Activation” and “Bile Acid
Biosynthesis”. These pathways are made up of genes involved
in the regulation of bile acid levels within hepatocytes and sup-
port recent studies implicating alterations in bile acid homeo-
stasis as a possible mechanism underlying tolvaptan DILI (Slizgi
et al., 2016; Woodhead et al., 2016).
The levels of 2 individual genes, Slpi and Wfdc12, were also
found to change not only with tolvaptan treatment but also to
differentiate sensitive and resistant strains. Both genes appear
to play a similar role in regulating immune response. Slpi inhib-
its nuclear factor kappa B (NF-kB)-dependent proinflammatory
signaling (Reeves et al., 2013; Williams et al., 2006), and macro-
phages secrete Slpi in response to phagocytosis of apoptotic
cells (Odaka et al., 2003). Therefore, the elevations of Slpi
observed in the present study may indicate an initial inflamma-
tory response, apoptosis, and subsequent macrophage activa-
tion in the livers of sensitive tolvaptan-treated animals. A
similar mechanism has been proposed to explain the elevation
in SLPI mRNA and Slpi protein observed in the livers of patients
with AALF (Antoniades et al., 2014). Liver levels corresponded to
Slpi elevations in plasma samples of AALF patients—a finding
that translated to this study. As susceptible mice in this study
had minimal elevations in serum ALT and no histological evi-
dence of liver injury, blood levels of Slpi levels may be elevated
in the plasma of patients prior to clinical evidence of tolvaptan
DILI.
More importantly, Slpi provides a potential connection
between the initial drug-induced cellular stress occurring at the
hepatocyte level and a delayed adaptive immune response. In
addition to inhibiting the proinflammatory response, elevated
Slpi levels also suppress secondary immune response (immune
tolerance) by inhibiting regulatory T-cell differentiation (Muller
et al., 2012). There is strong support that the loss of immune tol-
erance is a critical step in the pathogenesis of IDILI (Mosedale
and Watkins, Accepted). Taken together, this suggests that
tolvaptan-induced elevations in Slpi in sensitive strains may
ultimately result in loss of immune tolerance and precede the
onset of an adaptive immune attack.
A proposed alternative explanation for the delay in liver
injury observed in ADPKD patients is the contribution of disease
progression to DILI susceptibility (Watkins et al., 2015;
Woodhead et al., 2016). Interestingly, both rodent models of
ADPKD and ADPKD patients have increased bile acid concentra-
tions and inflammatory cytokines in liver cyst fluid (Li et al.,
2008; Munoz-Garrido et al., 2015), and in this study genes and
pathways implicated in altering bile acid homeostasis and
immune response were found to be associated with tolvaptan-
induced liver stress in the sensitive CC strains. It is therefore
conceivable that these findings reflect specific DILI risk factors
associated with disease progression among ADPKD patients.
Finally, pathways associated with tolvaptan treatment, inde-
pendent of response suggested tolvaptan-induced alterations in
immune signaling and oxidative stress in all animals, regardless
of susceptibility to liver stress. These findings are supported by
a recently published study demonstrating oxidative stress and
apoptosis in HepG2 (hepatocellular carcinoma) cells exposed to
tolvaptan (Wu et al., 2015). However, given that oxidative stress
was not associated with ALT elevations in the mice (and that
oxidative stress was observed in HepG2 cells), it may not under-
lie susceptibility to tolvaptan DILI.
In conclusion, 3 of the 45 CC strains evaluated in this study
were found to be sensitive to tolvaptan-induced liver stress.
Plasma drug concentration levels were only minimally corre-
lated with the degree of liver response. Genetic mapping identi-
fied a locus associated with tolvaptan-induced liver stress on
chromosome 14 that contained 3 candidate genes previously
implicated in liver injury. eQTL mapping also identified 4 new
molecular phenotypes as well as variants influencing their
response. Finally, gene expression profiling was used to gain a
mechanistic understanding of the liver response and suggests
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alterations in bile acid homeostasis are most likely to underlie
susceptibility to the stress in sensitive strains. Together with
mitochondrial dysfunction and oxidative stress, which were
observed in all tolvaptan-treated CC mice, these findings may
reflect early hepatocyte stress, even in the absence of overt
injury. In sensitive strains, these events were associated with
the release of Slpi, consistent with an innate immune response
and suppression of immune tolerance. Eventually, these events
may promote an adaptive immune attack and overt liver injury.
Taken together, the findings from this CC study may now guide
a targeted, hypothesis-based approach to biomarker discovery
in the DNA and sequential samples of plasma and urine that
were collected and archived from clinical trials. The ultimate
goal of this research is to inform a precision medicine approach
to manage the risk of DILI in tolvaptan-treated patients.
SUPPLEMENTARY DATA
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